Overview

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

The SATROPIN study is an international, multicenter, open-label, single-arm, phase II clinical trial to assess whether the use of prophylactic administration of atropine may prevent diarrhea in participants with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive/HER2-negative (HR(+)/HER2-) treated with sacituzumab govitecan.

Phase:

PHASE2

Details

Lead Sponsor:

MedSIR

Treatments:

Atropine
Filgrastim
Granulocyte Colony-Stimulating Factor
sacituzumab govitecan